VEXT Stock Overview
Through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Vext Science, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$0.20 |
| 52 Week High | CA$0.42 |
| 52 Week Low | CA$0.16 |
| Beta | 1.7 |
| 11 Month Change | -11.36% |
| 3 Month Change | -17.02% |
| 1 Year Change | -39.06% |
| 33 Year Change | -74.68% |
| 5 Year Change | -73.29% |
| Change since IPO | -86.07% |
Recent News & Updates
Recent updates
It's Down 26% But Vext Science, Inc. (CSE:VEXT) Could Be Riskier Than It Looks
Oct 24
Take Care Before Jumping Onto Vext Science, Inc. (CSE:VEXT) Even Though It's 30% Cheaper
Jun 18There Is A Reason Vext Science, Inc.'s (CSE:VEXT) Price Is Undemanding
Jan 16Is Now The Time To Put Vext Science (CSE:VEXT) On Your Watchlist?
Sep 29Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Aug 16Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Jan 17Shareholders May Be More Conservative With Vext Science, Inc.'s (CSE:VEXT) CEO Compensation For Now
Dec 09We Think Vext Science (CSE:VEXT) Can Stay On Top Of Its Debt
Sep 29Vext Science (CSE:VEXT) Seems To Use Debt Quite Sensibly
Apr 29Does Vext Science (CSE:VEXT) Have A Healthy Balance Sheet?
Nov 15Is Vext Science (CSE:VEXT) A Risky Investment?
Jul 15Weak Statutory Earnings May Not Tell The Whole Story For Vext Science (CSE:VEXT)
Apr 25Based On Its ROE, Is Vext Science, Inc. (CSE:VEXT) A High Quality Stock?
Jan 15Shareholder Returns
| VEXT | CA Pharmaceuticals | CA Market | |
|---|---|---|---|
| 7D | 5.4% | -6.1% | 0.7% |
| 1Y | -39.1% | -22.3% | 21.7% |
Return vs Industry: VEXT underperformed the Canadian Pharmaceuticals industry which returned -22.8% over the past year.
Return vs Market: VEXT underperformed the Canadian Market which returned 21.4% over the past year.
Price Volatility
| VEXT volatility | |
|---|---|
| VEXT Average Weekly Movement | 12.8% |
| Pharmaceuticals Industry Average Movement | 11.5% |
| Market Average Movement | 8.3% |
| 10% most volatile stocks in CA Market | 17.6% |
| 10% least volatile stocks in CA Market | 2.9% |
Stable Share Price: VEXT has not had significant price volatility in the past 3 months compared to the Canadian market.
Volatility Over Time: VEXT's weekly volatility (13%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | n/a | Eric Offenberger | www.vextscience.com |
Vext Science, Inc., through its subsidiaries, operates as an integrated agricultural technology, services, and property management company in the cannabis industry in the United States. It owns and manages cultivation facilities, manufacturing units, and dispensaries; and involves in the cultivation, extraction, manufacture, and sale of THC and CBD cartridges, concentrates, and edibles. The company also engages in the retail dispensary activities; and wholesale distribution of cannabis THC and hemp CBD products under the Vapen, Pure Touch, Appalachian Pharm, Herbal Wellness, and Revibe brands.
Vext Science, Inc. Fundamentals Summary
| VEXT fundamental statistics | |
|---|---|
| Market cap | CA$45.77m |
| Earnings (TTM) | -CA$9.69m |
| Revenue (TTM) | CA$46.60m |
1.0x
P/S Ratio-5.0x
P/E RatioIs VEXT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| VEXT income statement (TTM) | |
|---|---|
| Revenue | US$33.33m |
| Cost of Revenue | US$25.78m |
| Gross Profit | US$7.55m |
| Other Expenses | US$14.49m |
| Earnings | -US$6.93m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 21, 2024
| Earnings per share (EPS) | -0.028 |
| Gross Margin | 22.67% |
| Net Profit Margin | -20.80% |
| Debt/Equity Ratio | 40.6% |
How did VEXT perform over the long term?
See historical performance and comparison